Loading clinical trials...

Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1% | Clinical Trials | Clareo Health

COMPLETEDPhase 3NCT02236403

Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%

Blepharitis is a endemic inflammatory disease caused mainly by Demodex folliculorum and Demodex Brevis, This mites are often associated with anaerobic bacteria that produces a skin inflammation, so a ...

Lead sponsor: Universidad Nacional de Colombia•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment60

Start dateOct 2014

Last updatedMay 6, 2021

Condition

Chronic Blepharitis

Locations shown

Hospital de Engativa

Bogotá

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 6, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions